Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces ...

Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced U.S. Food and Drug Administration approval of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous ...

The Food and Drug Administration (FDA) has approved Boruzu (bortezomib injection), a new presentation of Velcade (bortezomib), for ready-to-use subcutaneous (under the skin) or intravenous (IV) ...

Fresenius Kabi Bortezomib for Injection is available in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the most recent TreatmentTrends ®: Multiple ...

RELATED: Subcutaneous Velcade more tolerable in multiple myeloma trial. The median number of prior lines of therapy for the 29 patients was seven. Of those, 25 were triple class-refractory, ...

Sarclisa, combined with Velcade, Revlimid, and dexamethasone, was approved for newly diagnosed multiple myeloma patients ineligible for ASCT, reducing disease progression risk by 40%. Retevmo was ...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. 2024-01-25. DOI: 10.1056/NEJMdo007367. ... The addition of subcutaneous daratumumab to bortezomib, ...

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration. Sep. 05, 2024 4:05 PM ET Amneal Pharmaceuticals, Inc. (AMRX) ...